Relapsed/Refractory Hematologic Malignancies
1 clinical trials · Condition
◉ Watch Relapsed/Refractory Hematologic Malignancies
| Record | Firm | Date |
|---|---|---|
| A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma (NCT07678307) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-30 |
Track Relapsed/Refractory Hematologic Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.